Interpace Biosciences, Inc. IDXG
· data as of November 13, 2026
Interpace Biosciences, Inc. (IDXG) is a company listed in the US with a market value of about $25M. In the twelve months to June 30, 2026 it had revenue of $36M and net income of $24M, a net margin of 67.6%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is financial health (5/5); the weakest is future growth (1/5).
Key numbers: a P/E of 1.0, a price to free cash flow of 6.0, 5-year revenue growth of 4% a year, a 5-year average ROIC of 118%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 5% below the current price.
About Interpace Biosciences
Interpace Biosciences is listed in the US. Revenue went from $24M in 2019 to $39M in 2025, growth of about 8.1% a year. It was profitable in 3 of the last 7 years in our data. Its share count rose by 553% over three years (dilution for shareholders). It spends 2% of revenue on research and development.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/FCF below 20
- Profit margin improving
- 5-year average ROIC above 12%
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36M | $39M | $47M | $40M | $32M | $33M | $32M | $24M |
| Net income | $24M | $25M | $7M | $2M | -$22M | -$15M | -$26M | -$27M |
| Free cash flow | $4M | $5M | $4M | $3M | -$8M | -$9M | -$16M | -$19M |
| EPS (diluted) | $0.89 | $0.89 | $0.40 | $0.45 | $-5.18 | $-3.61 | $-7.32 | $-7.25 |
| Net margin | 67.6% | 63.5% | 14.3% | 4.9% | -69.0% | -45.1% | -81.6% | -110.4% |
| ROIC | — | 13.7% | 222.7% | — | — | — | — | -722.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Interpace Biosciences’s P/E ratio?
About 1.0, based on the last twelve months of diluted earnings per share.
Is Interpace Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 5% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Interpace Biosciences pay a dividend?
Not currently.
Is Interpace Biosciences a good stock to buy?
We do not give buy or sell advice. Interpace Biosciences scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.